British health authorities stated that the UK has become the first nation to approve a bivalent Moderna Covid booster vaccination. Covid booster vaccination targets both the original strain of COVID-19 and the more recent Omicron version. The Moderna Covid booster vaccination was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as a “sharpened instrument” against the new coronavirus after it was determined to meet its requirements of safety, quality, and effectiveness.
Covid booster vaccination: Key Points
- Each dosage of the Moderna Covid booster vaccination “Spikevax bivalent Original/Omicron” contains 25 micrograms of vaccine that targets both the original viral strain from 2020 and Omicron.
- According to the authorities, safety monitoring revealed that there were no significant safety issues in the Moderna Covid booster vaccination, and that the side effects were generally modest and self-resolving, just like they were with the original Moderna booster dose.
- As part of the nation’s booster vaccine deployment programme, the independent Joint Committee on Vaccination and Immunization (JCVI) of the UK will now provide recommendations on how this new vaccine should be implemented.
- Additionally, the vaccine has been requested that the Australian, Canadian, and European Union regulatory bodies approve it (EU). By the end of next month, the dose is anticipated to receive approval from the EU drugs authority.
Covid booster vaccination: Important Takeaways
- MHRA Chief Executive: Dr June Raine
- Chair of the Commission on Human Medicines: Professor Sir Munir Pirmohamed